Literature DB >> 18315557

Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.

J Harenberg, Y Vukojevic, G Mikus, I Joerg, C Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18315557     DOI： 10.1111/j.1538-7836.2008.02943.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  6 in total

Review 1.  New anticoagulants - promising and failed developments.

Authors:  Job Harenberg; Svetlana Marx; Martin Krejczy; Martin Wehling
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 2.  Inhibitors of propagation of coagulation: factors V and X.

Authors:  Vincenzo Toschi; Maddalena Lettino
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  Pentasaccharides for the treatment of deep vein thrombosis.

Authors:  Gustavo Ms Brandao; Daniela R Junqueira; Hamilton A Rollo; Marcone L Sobreira
Journal:  Cochrane Database Syst Rev       Date:  2017-12-02

Review 4.  Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yanzhi Song; Xiaodong Li; Settipalli Pavithra; Dong Li
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

Review 5.  Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.

Authors:  Antonio Gómez-Outes; M Luisa Suárez-Gea; Ramón Lecumberri; Ana Isabel Terleira-Fernández; Emilio Vargas-Castrillón; Eduardo Rocha
Journal:  Vasc Health Risk Manag       Date:  2013-05-08

Review 6.  Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions.

Authors:  Jinlei Li; Thomas Halaszynski
Journal:  Local Reg Anesth       Date:  2015-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.